Karyopharm Therapeutics Inc. KPTI

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).

KPTI hizo una agrupación de acciones (split inverso) de 1:15 el 26 de febrero de 2025: cada 15 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 3 sept

  Advanced Endometrial Cancer Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Advanced Endometrial Cancer Therapeutics Space | DelveInsight

  DelveInsight released a comprehensive analysis of the advanced endometrial cancer clinical trial pipeline, identifying 25+ active pharmaceutical companies developing 26+ pipeline drugs. The report highlights emerging therapies including immunotherapies, targeted agents, and antibody-drug conjugates (ADCs) from major players like Pfizer, Genmab, and Incyte Corporation. Recent developments include FDA Fast Track designation for Faeth Therapeutics' PIKTOR combination therapy and positive Phase III results for Merck's sacituzumab tirumotecan, indicating significant momentum in reshaping the advanced endometrial cancer treatment landscape.

  

• GlobeNewswire Inc. 4 ago

  INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI

  Pomerantz LLP is investigating potential securities fraud claims against Karyopharm Therapeutics following the company's disclosure of a retention program offering executives cash awards ranging from $625,000 to $1,725,000. The announcement triggered a significant stock price decline of 21.45% on July 20, 2026, closing at $7.47 per share.

  

• GlobeNewswire Inc. 14 jun

  Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

  Menarini Group and Stemline Therapeutics announced positive Phase 3 SENTRY trial results showing that selinexor combined with ruxolitinib met the primary endpoint for spleen volume reduction (SVR35) at 49.8% versus 28% for ruxolitinib alone in myelofibrosis patients. The combination also demonstrated a promising early overall survival signal with greater than 50% reduction in death risk, though it did not meet the secondary symptom score endpoint. The safety profile was manageable with no new safety signals observed.